Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study on Persistence on Certolizumab and Predictors Thereof in with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial-Spondyloarthritis Patients-Apulian Biopure Registry

Trial Profile

Study on Persistence on Certolizumab and Predictors Thereof in with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial-Spondyloarthritis Patients-Apulian Biopure Registry

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2018

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jul 2018 New trial record
    • 16 Jun 2018 Results assessing Drug Survival on Certolizumab, presented at the 19th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top